Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma

NCT01026220 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01026220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01026220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
December 7, 2009
Completion date
March 31, 2022
Enrollment
166 (actual)
Sites
177

Conditions

As the registry lists them; a condition with its own page is linked.

childhood nodular lymphocyte predominant hodgkin lymphoma, stage iii childhood hodgkin lymphoma, stage iv childhood hodgkin lymphoma